The patent at the center of the lawsuit is based on research by a professor in the University of Minnesota’s college of pharmacy. The university claims its intellectual property covers Gilead drugs that contain sofosbuvir, including the company’s two hepatitis C drugs Harvoni and Sovaldi. Those two drugs have generated $20 billion in revenue for Gilead, according to the report.
Gilead disputed the university’s allegations. “We believe the University of Minnesota’s patent is invalid and is not infringed by the sale of Gilead’s medicines for chronic hepatitis C,” Gilead said in a prepared statement.
More articles on healthcare industry lawsuits:
Employee accuses Oregon hospital of wage theft, discrimination and retaliation
12 latest healthcare industry lawsuits, settlements
NYC high-rise sues Hospital for Special Surgery
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.